Leukemia

U.S. FDA grants orphan drug designation to acute myelogenous leukemia drug

Published in Medical Letter on the CDC and FDA, November 28th, 2004

Vion Pharmaceuticals, Inc. (VION) announced that it has been granted orphan drug designation from the U.S. Food and Drug Administration for Cloretazine (VNP40101M) for the treatment of acute myelogenous leukemia.

Cloretazine (VNP40101M) is a sulfonylhydrazine alkylating agent that is being evaluated by the company in a phase 2 clinical trial for acute myelogenous leukemia.

The company plans to commence a phase 3 trial of Cloretazine in combination with Ara-C in relapsed acute myelogenous leukemia no later than the first quarter of 2005.

Orphan drug designation may be granted to products that treat rare diseases or conditions that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-11-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry